Biotech · Private company
Intarcia Therapeutics
Track this companyFree. Adds Intarcia Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Empagliflozin (oral)Phase 3 · Diabetes Mellitus, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- Glimepiride (oral)Phase 3 · Diabetes Mellitus, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ITCA 650 (exenatide in DUROS)Phase 3 · Type 2 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- ITCA 650 20/60 mcg/dayPhase 3 · Diabetes Mellitus, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminPHASE3 · TERMINATED · started Mar 3, 2017ClinicalTrials.gov NCT03060980 · fetched Nov 12, 2026
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cPHASE3 · TERMINATED · started May 1, 2013ClinicalTrials.gov NCT01785771 · fetched Nov 12, 2026